GLP1_NEW
Semaglutide and bimagrumab 2.4 to 30 mg injection once weekly
BIMASEMA_SC_2p4-30MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 40 to 104 (target week 68) | Placebo | MD -3.49 (-14.54 to 8.06) | 0.72 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 32.49 (5.57 to 274) | 0.72 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 65.67 (14.59 to 356) | 0.96 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 40.91 (13.54 to 124) | 0.98 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.99 (0.31 to 3.17) | 0.55 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.07 (0.23 to 3.89) | 0.66 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.56 (1.93 to 6.73) | 0.50 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.95 (1.05 to 8.18) | 0.63 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.01 (1.99 to 8.06) | 0.19 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.37 (0.48 to 3.76) | 0.65 |